Chardan Capital Has Lowered Expectations for Prime Medicine (NYSE:PRME) Stock Price
Prime Medicine (NYSE:PRME – Get Free Report) had its price target decreased by stock analysts at Chardan Capital from $16.00 to $12.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. A number of other research analysts have also recently commented on PRME. StockNews.com raised shares of […]
Prime Medicine (NYSE:PRME – Get Free Report) had its price target decreased by stock analysts at Chardan Capital from $16.00 to $12.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. A number of other research analysts have also recently commented on PRME. StockNews.com raised shares of […]
